Zelandopam hydrochloride

Drug Profile

Zelandopam hydrochloride

Alternative Names: MYD 37; YM 435

Latest Information Update: 22 May 2002

Price : $50

At a glance

  • Originator Yamanouchi
  • Developer Mochida Pharmaceutical; Yamanouchi
  • Class Antihypertensives; Vasodilators
  • Mechanism of Action Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Heart failure; Hypertension

Most Recent Events

  • 22 May 2002 YM 435 is now called Zelandopam hydrochloride
  • 22 Dec 2000 No-Development-Reported for Hypertension in Japan (IV)
  • 22 Dec 2000 No-Development-Reported for Heart failure in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top